Clinical immunology最新文献_第3页

Clinical spectrum of Wiskott-Aldrich syndrome carriers: Self-reported survey of 193 carriers Wiskott-Aldrich综合征携带者的临床谱：对193名携带者的自我报告调查。

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-02-01 Epub Date: 2025-12-17 DOI: 10.1016/j.clim.2025.110658

Shanmuganathan Chandrakasan , Adrianna Westbrook , Linda M. Griffith , David Hagin , Sumathi Iyengar , Christina Mangurian , Chris Scalchunes , Kathleen E. Sullivan , Akiva Zablocki , Nitya Bakshi , Cynthia Sinha , Lauri M. Burroughs , Alice Y. Chan , Christopher C. Dvorak , Elie Haddad , Jennifer Heimall , Donald B. Kohn , Jennifer W. Leiding , Luigi D. Notarangelo , Sung-Yun Pai , Suhag Parikh

{"title":"Clinical spectrum of Wiskott-Aldrich syndrome carriers: Self-reported survey of 193 carriers","authors":"Shanmuganathan Chandrakasan , Adrianna Westbrook , Linda M. Griffith , David Hagin , Sumathi Iyengar , Christina Mangurian , Chris Scalchunes , Kathleen E. Sullivan , Akiva Zablocki , Nitya Bakshi , Cynthia Sinha , Lauri M. Burroughs , Alice Y. Chan , Christopher C. Dvorak , Elie Haddad , Jennifer Heimall , Donald B. Kohn , Jennifer W. Leiding , Luigi D. Notarangelo , Sung-Yun Pai , Suhag Parikh","doi":"10.1016/j.clim.2025.110658","DOIUrl":"10.1016/j.clim.2025.110658","url":null,"abstract":"<div><div>Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder with microthrombocytopenia, eczema, immunodeficiency, autoimmunity and malignancies resulting from WAS pathogenic variants. Prevalence of disease in heterozygous female carriers has not been described previously.</div><div>An online Qualtrics survey was designed in collaboration with the Wiskott-Aldrich Foundation, the Immune Deficiency Foundation, the Primary Immune Deficiency Treatment Consortium and Emory University to describe the incidence of thrombocytopenia, eczema, infections, autoimmune disorders, malignancies, and psychosocial factors.</div><div>193 carriers with a median age of 39 years participated in this survey. Respondents were predominantly White and were mothers of WAS patients. We observed a high prevalence of thrombocytopenia (13 %), eczema (22 %), infections (33 %) and autoimmunity (24 %) in this self-reported survey. No hematological malignancies were reported. Guilt (91 %), anxiety (41 %) and depression (44 %) were very prevalent.</div><div>Comprehensive clinical and immunologic studies of WAS carriers should be prioritized to define appropriate health screening, preventive approaches, and counselling for carriers.</div></div><div><h3>Summary</h3><div>This self-reported survey describes the disease burden in 193 carriers of X-linked Wiskott-Aldrich syndrome. It highlights the increased incidence of thrombocytopenia, eczema, infections and autoimmunity in WAS carriers and the need for more comprehensive studies of WAS carriers.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"283 ","pages":"Article 110658"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term immune and epigenetic dysregulation following COVID-19 COVID-19后的长期免疫和表观遗传失调。

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-02-01 Epub Date: 2025-12-13 DOI: 10.1016/j.clim.2025.110656

Chrysanthi Sidiropoulou , Garyphallia Poulakou , Evdoxia Kyriazopoulou , Elisavet Tasouli , Efthymia Giannitsioti , Anna Strikou , Maria Tsilika , Eirini Christaki , Vassiliki Rapti , Vassiliki Evangelopoulou , Nikoletta Rovina , Nathalie Iannotti , Emanuele Nicastri , Eleonora Taddei , Helena Florou , Andrea Angheben , Matteo Bassetti , Lorenzo Dagna , Antonio Torres , Spyros Foutadakis , Evangelos J. Giamarellos-Bourboulis

{"title":"Long-term immune and epigenetic dysregulation following COVID-19","authors":"Chrysanthi Sidiropoulou , Garyphallia Poulakou , Evdoxia Kyriazopoulou , Elisavet Tasouli , Efthymia Giannitsioti , Anna Strikou , Maria Tsilika , Eirini Christaki , Vassiliki Rapti , Vassiliki Evangelopoulou , Nikoletta Rovina , Nathalie Iannotti , Emanuele Nicastri , Eleonora Taddei , Helena Florou , Andrea Angheben , Matteo Bassetti , Lorenzo Dagna , Antonio Torres , Spyros Foutadakis , Evangelos J. Giamarellos-Bourboulis","doi":"10.1016/j.clim.2025.110656","DOIUrl":"10.1016/j.clim.2025.110656","url":null,"abstract":"<div><div>Post-Acute COVID-19 syndrome (PACS) is heterogeneous in phenotype and functional state. This prospective, observational study studied adults six months after acute COVID-19. We defined clinical phenotypes and profiled plasma mediators grouped into functional pathways (IL-1, IL-17, IFNγ/IFNγ-related cytokines, pro−/anti-inflammatory clusters). A subset underwent RNA-seq and ChIP-seq experiments. Three cohorts were analyzed (Exploratory <em>n</em> = 46; Discovery <em>n</em> = 591; Validation Cohort <em>n</em> = 289). PACS compatible symptoms were identified in 69.6 %; 59.2 % and 54.7 % respectively. Five phenotypes emerged. IL-1 cytokines (OR: 3.17, 95 % CIs: 1.94–5.19, p: 4.5 × 10<sup>−6</sup>), IL-17 cytokines (OR: 2.45, 95 % CIs: 1.47–4.07 p: 5.88 × 10<sup>−4</sup>) and the anti-inflammatory biomarkers (OR: 2.15, 95 % CIs: 1.34–3.45, p: 1.5 × 10<sup>−3</sup>) were upregulated in PACS patients. Respiratory phenotype was correlated with IL-1 upregulation (OR 4.23; 95 % CIs, 1.69–10.8, <em>p</em> = 0.0025). Transcriptomic and epigenomic changes were observed. Distinct phenotypes of PACS are driven by different immunological mechanisms at the DNA, transcriptomic, and protein levels.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"283 ","pages":"Article 110656"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145755432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic cytokine profiling enhances the performance of dd-cfDNA to detect cardiac rejection 系统细胞因子谱增强了dd-cfDNA检测心脏排斥反应的性能。

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-02-01 Epub Date: 2025-12-21 DOI: 10.1016/j.clim.2025.110659

Temesgen E. Andargie , Han Su , Moon Kyoo Jang , Xin Tian , Andrew H. Karaba , Sean Agbor-Enoh

引用次数: 0

Cross-reactive HERV-W and EBV peptides elicit antibody responses in MS patients and synergistically exacerbate neuroinflammation in EAE 交叉反应的HERV-W和EBV肽在MS患者中引起抗体反应，并协同加剧EAE的神经炎症

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-02-01 Epub Date: 2025-11-23 DOI: 10.1016/j.clim.2025.110644

Davide Cossu , Yuji Tomizawa , Tamami Sakanishi , Stefano Ruberto , Taku Hatano , Nobutaka Hattori

{"title":"Cross-reactive HERV-W and EBV peptides elicit antibody responses in MS patients and synergistically exacerbate neuroinflammation in EAE","authors":"Davide Cossu , Yuji Tomizawa , Tamami Sakanishi , Stefano Ruberto , Taku Hatano , Nobutaka Hattori","doi":"10.1016/j.clim.2025.110644","DOIUrl":"10.1016/j.clim.2025.110644","url":null,"abstract":"<div><div><em>Human endogenous retrovirus W</em> (HERV-W) has been linked to multiple sclerosis (MS), yet its pathogenic role remains unclear. <em>Epstein–Barr virus</em> (EBV), a key MS risk factor, can transactivate HERVs, suggesting a potential interplay. We analyzed immune responses to a HERV-W₁₀₃–₁₁₀ peptide homologous to EBV EBNA1₃₈₆–₄₀₅ in sera from Japanese MS patients (<em>n</em> = 44), neurological controls (<em>n</em> = 28), and healthy controls (<em>n</em> = 48), including an unrelated control antigen (BCG) to assess general humoral activation. MS patients exhibited elevated antibodies to both peptides, indicating cross-reactive immunity. In C57BL/6 J mice, pre-immunization with either peptide modestly modulated experimental autoimmune encephalomyelitis (EAE), whereas combined pre-immunization exacerbated disease, expanding CD4<sup>+</sup> and CD8<sup>+</sup> T cells and promoting systemic activation. These results support a model in which EBV-driven HERV-W activation elicits cross-reactive humoral and cellular responses that amplify neuroinflammation in MS.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"283 ","pages":"Article 110644"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis Eculizumab作为胸腺瘤相关性重症肌无力围手术期治疗的新选择。

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-02-01 Epub Date: 2025-12-16 DOI: 10.1016/j.clim.2025.110657

Hui Wu , Xianglin Chu , Huahua Zhong , Ying Huang , Hongxia Yang , Guoyan Qi , Lei Jin , Ran Chen , Wenji Jia , Ji Xiong , Liewen Pang , Chongbo Zhao , Jie Song , Sushan Luo

{"title":"Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis","authors":"Hui Wu , Xianglin Chu , Huahua Zhong , Ying Huang , Hongxia Yang , Guoyan Qi , Lei Jin , Ran Chen , Wenji Jia , Ji Xiong , Liewen Pang , Chongbo Zhao , Jie Song , Sushan Luo","doi":"10.1016/j.clim.2025.110657","DOIUrl":"10.1016/j.clim.2025.110657","url":null,"abstract":"<div><div>The efficacy of eculizumab as a perioperative treatment in patients with thymoma-associated myasthenia gravis (TAMG) has not been evaluated. This prospective study included patients with TAMG who received standard-of-care therapy (Soc group, <em>n</em> = 20) or combined with eculizumab (Ecu group, <em>n</em> = 13). At 1 week, the Ecu group showed a marked improvement compared to the Soc group, as evidenced by a reduction in Quantitative Myasthenia Gravis (QMG) (7.39 ± 3.47 vs 0.25 ± 5.13, <em>P</em> <em>=</em> 0.0001), Manual Muscle Test (MMT) (6.39 ± 4.66 vs 0.15 ± 3.96, <em>P</em> = 0.0003), and MG Activities of Daily Living (MG-ADL) (4.85 ± 3.16 vs 0.30 ± 3.47, <em>P</em> = 0.0006). No significant differences were observed in operative time, or intraoperative blood loss. The rate of postoperative myasthenic crisis was 9.1 % (1/13) in the Ecu group, compared to 20 % (4/20) in the Soc group (<em>P</em> = 0.33). This study highlights the role of eculizumab in TAMG as a rapid symptom-control treatment before thymomectomy.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"283 ","pages":"Article 110657"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulation of Ro52/SSA autoantigen by endoplasmic reticulum stress and ERK1/2-mTOR-autophagy signaling pathway in primary Sjögren disease 内质网应激和erk1 /2- mtor自噬信号通路对原发性Sjögren疾病中Ro52/SSA自身抗原的调控

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-02-01 Epub Date: 2025-12-11 DOI: 10.1016/j.clim.2025.110655

Qianwen Tian , Qi Xi , Qiaolin Zhang , Yun Chen , Yunxin Zhang , Fuxue Kuang , Lejie Sun , Song Peng , Huaxun Wu

{"title":"Regulation of Ro52/SSA autoantigen by endoplasmic reticulum stress and ERK1/2-mTOR-autophagy signaling pathway in primary Sjögren disease","authors":"Qianwen Tian , Qi Xi , Qiaolin Zhang , Yun Chen , Yunxin Zhang , Fuxue Kuang , Lejie Sun , Song Peng , Huaxun Wu","doi":"10.1016/j.clim.2025.110655","DOIUrl":"10.1016/j.clim.2025.110655","url":null,"abstract":"<div><div>Primary Sjögren disease (pSS) is an autoimmune disease characterized primarily by predominant lymphocytic infiltration of the exocrine glands. While the etiopathogenesis of pSS remains unclear, current therapeutic strategies lack efficacy. In human submandibular gland epithelial cells (HSGECs), endoplasmic reticulum stress (ERS) induces apoptosis, leading to the cellular redistribution of Ro52/SSA autoantigens, the activation of the immune system, and the production of a large number of autoantibodies. Cells initiate autophagy to resist cellular damage caused by ERS and restore the normal physiological status. The ERK1/2-mTOR-autophagy signaling pathway has been implicated in numerous pathological conditions. In this study, an experimental Sjögren disease (ESS) mouse model was established to evaluate reduced protein levels and altered intracellular distribution of Ro52/SSA autoantigens through modulation of ERS and the ERK1/2-mTOR-autophagy pathway, resulting in diminished autoantibody production and ameliorated ESS symptoms. These findings provide an experimental foundation for therapeutic strategies targeting Ro52/SSA production in pSS.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"283 ","pages":"Article 110655"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry 活化磷酸肌肽3-激酶δ综合征（APDS）临床表现的自然史：使用欧洲免疫缺陷学会-APDS注册的时间-事件分析。

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-02-01 Epub Date: 2025-10-31 DOI: 10.1016/j.clim.2025.110632

Maria Elena Maccari , Sven Kracker , Anita Chandra , Stephan Ehl , Markus G. Seidel , Joanne Tutein Nolthenius , Laura J. Clark , Jennifer Page , Annabel Griffiths , John Whalen

{"title":"Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry","authors":"Maria Elena Maccari , Sven Kracker , Anita Chandra , Stephan Ehl , Markus G. Seidel , Joanne Tutein Nolthenius , Laura J. Clark , Jennifer Page , Annabel Griffiths , John Whalen","doi":"10.1016/j.clim.2025.110632","DOIUrl":"10.1016/j.clim.2025.110632","url":null,"abstract":"<div><div>Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an ultra-rare, progressive disease characterised by immunodeficiency, immune dysregulation, and risk of malignancies. To further characterise the natural history of APDS, we analysed patient characteristics, manifestations, treatment use, and combinations of manifestations and combinations of treatments over time using longitudinal data from registration and follow-up visits in the European Society for Immunodeficiencies (ESID)-APDS registry. 140 patients were included (mean age: 17.7 years at registration; 19.1 years at last follow-up). Manifestation burden was high from childhood (patients experienced up to 9 manifestations by age 10). The number of treatments increased with age, with a 64 % probability of receiving ≥1 by age 10. Life-threatening APDS complications led to 13 deaths reported over 2.6 years' mean follow-up. These data highlight the chronic, progressive nature of APDS and its long-term impact on patients, with a high manifestation load and early mortality, despite widespread symptomatic treatment use.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"283 ","pages":"Article 110632"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145430450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epicutaneous application of house dust mite induces allergic skin inflammation and atopic march to the lung upon airway allergen challenge 屋尘螨的表皮应用引起过敏性皮肤炎症和特应性进军肺部气道过敏原的挑战。

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-02-01 Epub Date: 2025-11-29 DOI: 10.1016/j.clim.2025.110653

Fatima Hubaishi , Rami Karkout , Lydia Labrie , Raidan Mohammed Alyazidi , Magan Solomon , Haya Aldossary , Brian J. Ward , Elizabeth D. Fixman

{"title":"Epicutaneous application of house dust mite induces allergic skin inflammation and atopic march to the lung upon airway allergen challenge","authors":"Fatima Hubaishi , Rami Karkout , Lydia Labrie , Raidan Mohammed Alyazidi , Magan Solomon , Haya Aldossary , Brian J. Ward , Elizabeth D. Fixman","doi":"10.1016/j.clim.2025.110653","DOIUrl":"10.1016/j.clim.2025.110653","url":null,"abstract":"<div><div>Atopic dermatitis (AD) in infants is associated with increased risk of developing other allergic diseases, including asthma. This progression is known as atopic march (AM). We established a murine AM model by first inducing AD-like skin inflammation to house dust mite (HDM) allergen. Mice were subsequently challenged with HDM delivered to the lung. Our data show that epicutaneous sensitization with HDM increased serum IgE, ear thickness, and immune cell infiltration into the skin, accompanied by an increase in CD4<sup>+</sup> tissue-resident memory T cells (Trm) in the lung. Following pulmonary HDM challenge, eosinophil influx and T2 inflammation were increased in the lung. Together, our data suggest communication between the skin and lung, where allergen sensitization on the skin increases lung Trm and amplifies the T2 allergic response to lung allergen challenge. This clinically relevant model could help identify novel targets for local interventions to reduce the progression of AD to asthma.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"283 ","pages":"Article 110653"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An integrated biomarker panel for early computational prediction of dengue severity during the acute phase 一个集成的生物标志物面板，用于登革热急性期严重程度的早期计算预测。

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-01-01 Epub Date: 2025-11-19 DOI: 10.1016/j.clim.2025.110642

Josephine Diony Nanda , Tzong-Shiann Ho , Rahmat Dani Satria , Yung-Ting Wang , Chun-Hao Lai , Ya-Lan Lin , Chiou-Feng Lin

{"title":"An integrated biomarker panel for early computational prediction of dengue severity during the acute phase","authors":"Josephine Diony Nanda , Tzong-Shiann Ho , Rahmat Dani Satria , Yung-Ting Wang , Chun-Hao Lai , Ya-Lan Lin , Chiou-Feng Lin","doi":"10.1016/j.clim.2025.110642","DOIUrl":"10.1016/j.clim.2025.110642","url":null,"abstract":"<div><div>Serum cytokines and chemokines play a pivotal role in dengue immunopathogenesis and may serve as biomarkers of disease severity. This study aimed to identify applicable blood biomarkers during the acute stage of infection to support early severity evaluation using Principal Component Analysis (PCA)–based feature integration. Ninety-two dengue patients were consecutively enrolled from hospital admissions with laboratory-confirmed dengue during the 2015–2017 epidemic. Only those with NS1-positive or PCR-positive cases were included in this study, spanning asymptomatic, symptomatic, and severe cases, which were assessed for hematological, viral, and cytokine/chemokine parameters. Key variables—platelet count, GPT, creatinine, NS1, NST, IL-18, RANTES, IL-6, IFN-α2, and IL-7—were incorporated into a Prediction Panel. Validation showed that several biomarker combinations achieved up to 90 % accuracy in distinguishing severity groups, while others reached ∼70 %. Principal component analysis further refined the panel, showing accuracy above 90 % when NS1 or NST were included (A–B: 92.1 %, A–C: up to 91.8 %). These findings highlight the potential of an integrated biomarker-based Prediction Panel for early and reliable assessment of dengue severity within the first week of illness.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"282 ","pages":"Article 110642"},"PeriodicalIF":3.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-titer IVIG 10 % (human)–slra reduces infections and hospitalizations over 6 to 12 months: A retrospective quality improvement study 高滴度IVIG 10 %（人）-slra减少感染和住院6至12 个月：一项回顾性质量改进研究。

IF 3.8 3区医学

Clinical immunology Pub Date : 2026-01-01 Epub Date: 2025-11-01 DOI: 10.1016/j.clim.2025.110633

Gabrielle Magdalena Tan , Kiran Sehmi , Sarah Azzi , Robert Hostoffer

{"title":"High-titer IVIG 10 % (human)–slra reduces infections and hospitalizations over 6 to 12 months: A retrospective quality improvement study","authors":"Gabrielle Magdalena Tan , Kiran Sehmi , Sarah Azzi , Robert Hostoffer","doi":"10.1016/j.clim.2025.110633","DOIUrl":"10.1016/j.clim.2025.110633","url":null,"abstract":"<div><div>Patients with primary or secondary immunodeficiencies are at an increased risk for recurrent respiratory infections despite standard intravenous immunoglobulin (IVIG) therapy. This retrospective quality improvement review evaluated the clinical impact of a high-titer IVIG product enriched with pathogen-specific antibodies in 14 patients after failing conventional IVIG. The primary outcomes were changes in infection frequency and hospitalization rates during the 6 months before and after treatment initiation, and from 6 months post-treatment to the present. Ten patients (71%) showed clinical improvement, with infections decreasing from 36 to 8 and hospitalizations from 14 to 5 in the first 6 months post-treatment; benefits were more pronounced when excluding one clinical outlier. Two patients discontinued therapy due to mild adverse effects or lack of efficacy. High-titer IVIG was associated with meaningful reductions in infection burden and hospitalizations, supporting its consideration for high-risk patients unresponsive to standard IVIG.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"282 ","pages":"Article 110633"},"PeriodicalIF":3.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145430445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0